Merck and Bayer's heart drug meets main goal of late-stage study

  • Mon,18 Nov 2019 01:01:56 PM

London Nov 18 (Reuters) - Merck & Co Inc said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.

The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients with worsening chronic heart failure compared to placebo, when given in combination with available therapies for the condition, Merck said. [nBw92S6T2a]

Leave a Comment

Title : Merck and Bayer's heart drug meets main goal of late-stage study

 
You have 2000 characters left.